Doug Evans

Doug Evans

CEO at Lungpacer Medical Inc.

Doug Evans, PE is the CEO of Lungpacer Medical Inc., which has developed a novel therapeutic neurostimulation technology for preserving the integrity and strength of the diaphragm muscle, and for providing protection of lungs and cognitive function in critically ill patients who require mechanical ventilation, a US $22 billion market opportunity. Lungpacer’s AeroPace System, approved by FDA in Dec 2024, was shown to wean patients from mechanical ventilation nearly 3 days faster and reduce the risk for reintubation at 30 days by up to 60%. He is an accomplished medical device executive, business leader, and strategist with 30 years of start-up, private, public/IPO experiences. He is a serial innovator of first-of-their-kind products, such as the Angio-Seal Vascular Closure Device, and has over 300 issued global patents covering dozens of devices, which have been used in over 15 million patients world-wide and generated greater than $4 billion in end-user sales. Doug serves as Chairman for TELA Bio, NASDAQ: TELA and Board member for private WhiteSwell Medical. Doug served as Board Member for Intact Vascular, acquired by Royal Philips for $360M in 2020, and as Chief Operating Officer and Board Member of Kensey Nash Corporation (NASDAQ: KNSY), acquired for $360M by Royal DSM in 2012. Doug is the co-founder of Cure4Cam Childhood Cancer Foundation, which seeks to raise community awareness about childhood cancers and supports the development of new and more humane therapies for children with these diseases.

Sessions
Lungpacer: Using Neurostim to Help Patients Breathe
Wednesday, April 30 1:30 PM - 2:15 PM